Sorafenib for relapsed FLT3‐ITD‐positive acute myeloid leukemia postallogeneic stem cell transplantation presenting as leukemia cutis

Relapse of FLT3‐mutated acute myeloid leukemia (AML) following allogeneic stem cell transplantation is associated with poor survival. The clinical utility of sorafenib monotherapy in this setting is described in a patient presenting as leukemia cutis.

Detalles Bibliográficos
Autores principales: Brodie, Rachel, Langabeer, Stephen E., Quinn, John, McMenamin, Máirín E., Hayden, Patrick J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Clinical Image
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6935638/
https://www.ncbi.nlm.nih.gov/pubmed/31893105
http://dx.doi.org/10.1002/ccr3.2487

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6935638/
https://www.ncbi.nlm.nih.gov/pubmed/31893105
http://dx.doi.org/10.1002/ccr3.2487

Ejemplares similares